Merck & Company Inc (MRK)vsUroGen Pharma Ltd (URGN)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
URGN
UroGen Pharma Ltd
$23.83
+2.10%
HEALTHCARE · Cap: $1.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 59115% more annual revenue ($65.01B vs $109.79M). MRK leads profitability with a 28.1% profit margin vs -139.8%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
URGN
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Intrinsic value data unavailable for URGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Revenue surging 54.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1481.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : URGN
The strongest argument for URGN centers on Revenue Growth, Debt/Equity. Revenue growth of 54.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : URGN
The primary concerns for URGN are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while URGN is a hypergrowth play — different risk/reward profiles.
URGN carries more volatility with a beta of 1.44 — expect wider price swings.
URGN is growing revenue faster at 54.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 28/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →UroGen Pharma Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
UroGen Pharma Ltd (URGN) is an innovative biotechnology company specializing in the development of specialized therapies for urological diseases, with a focus on urothelial carcinoma and bladder cancer. Leveraging its proprietary reverse thermal gel platform, UroGen enables targeted, sustained local drug delivery, thereby optimizing therapeutic efficacy while reducing systemic side effects. With a promising clinical pipeline addressing significant unmet medical needs in urology, UroGen is strategically poised to advance patient care and establish itself as a leader in the urological oncology space.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?